Jespersen Kathryn E, Xiong Wanfen, Santhanam Lakshmi, Terrin Michael, Matsumura Jon, Curci John A, Blackwelder William, Brown Clayton H, Martinez Yus Marta, Baxter B Timothy
University of Saint Mary, Leavenworth, Kansas, United States.
Nebraska Medical Center, University of Nebraska Medical Center, Omaha, Nebraska, United States.
Am J Physiol Heart Circ Physiol. 2025 Feb 1;328(2):H247-H259. doi: 10.1152/ajpheart.00163.2024. Epub 2024 Dec 24.
Abdominal aortic aneurysm (AAA) is a common, progressive, and potentially fatal dilation of the most distal aortic segment. Multiple studies with longitudinal follow-up of AAA have identified markedly slower progression among patients affected with diabetes. Understanding the molecular pathway responsible for the growth inhibition could have implications for therapy in nondiabetic patients with AAA. Toward this end, we investigated the effects of hyperglycemia in a murine model of AAA and a carefully monitored cohort of patients with AAA from the Noninvasive Treatment of AAA-Clinical Trial (NTA3CT). In mice with hyperglycemia, AAA growth was inhibited to a similar degree (∼30%) as seen in patients with diabetes. AAA growth correlated inversely to levels of hyperglycemia in mice and patients with AAA. Inhibiting lysyl oxidase (LOX) activity increases aneurysm growth and matrix degradation in this model. Hyperglycemia increased LOX concentration in aortic smooth muscle cells (SMCs) but not in murine AAA tissue. Inhibiting LOX activity completely blocked the growth-inhibitory effect of hyperglycemia. Lysyl oxidase-like 2 (LOXL2), the primary arterial isoform of LOX, is expressed in the same area as type IV collagen along the outer media in murine AAA tissue. There is a significant inverse correlation between LOXL2 and AAA growth rates in patients. Taken together, these studies suggest a role for LOXL2-mediated type IV collagen crosslinking in slowing AAA growth in the setting of hyperglycemia. AAA grows slower in patients affected by diabetes. This growth inhibition is lost when the enzyme lysyl oxidase (LOX) is blocked in diabetic mice. The predominant arterial isoform of LOX, LOX-like 2 (LOXL2), overlaps with type IV collagen in the outer media of murine aneurysm tissue. Circulating LOXL2 correlates inversely with AAA growth in patients. Type IV collagen cross-linking by LOXL2 may play a role in the AAA growth inhibition associated with diabetes.
腹主动脉瘤(AAA)是最远端主动脉段常见的、进行性的且具有潜在致命性的扩张病变。多项对AAA进行纵向随访的研究发现,糖尿病患者的AAA进展明显较慢。了解导致生长抑制的分子途径可能对非糖尿病性AAA患者的治疗具有重要意义。为此,我们在AAA小鼠模型以及来自腹主动脉瘤无创治疗临床试验(NTA3CT)的一组经过仔细监测的AAA患者中研究了高血糖的影响。在高血糖小鼠中,AAA的生长受到抑制,其程度与糖尿病患者相似(约30%)。AAA的生长与小鼠和AAA患者的高血糖水平呈负相关。在该模型中,抑制赖氨酰氧化酶(LOX)活性会增加动脉瘤生长和基质降解。高血糖会增加主动脉平滑肌细胞(SMC)中LOX的浓度,但不会增加小鼠AAA组织中的LOX浓度。抑制LOX活性完全阻断了高血糖的生长抑制作用。LOX的主要动脉异构体赖氨酰氧化酶样2(LOXL2)在小鼠AAA组织中外膜与IV型胶原相同的区域表达。患者中LOXL2与AAA生长速率之间存在显著的负相关。综上所述,这些研究表明在高血糖情况下,LOXL2介导的IV型胶原交联在减缓AAA生长中发挥作用。糖尿病患者的AAA生长较慢。当在糖尿病小鼠中阻断赖氨酰氧化酶(LOX)时,这种生长抑制作用消失。LOX的主要动脉异构体LOX样2(LOXL2)与小鼠动脉瘤组织外膜中的IV型胶原重叠。患者循环中的LOXL2与AAA生长呈负相关。LOXL2介导的IV型胶原交联可能在与糖尿病相关的AAA生长抑制中起作用。